Mandate

Vinge has advised Svea Bank AB in connection with the issuance of Additional Tier 1 Capital of SEK 300 million

March 14, 2023 Banking and Finance

Vinge has advised Svea Bank AB (the “Company”) in connection with its issuance of additional tier 1 capital (AT1) of SEK 300 million to optimise its capital structure.

The issuance is in the form of a debt instrument with automatic write-down of its nominal amount if the common equity tier 1 capital ratio of the Company falls below a certain level. The instruments will be listed on Nasdaq Stockholm. In connection with the issuance, the Company will also redeem the outstanding additional tier 1-bond, originally dated 3 April 2018, on 3 April 2023.

Vinge’s team consisted of Mikael Ståhl, Arvid Weimers and Calle Tengwall Pagels.

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025